HealthQuill Organon & Co
The US regulator has extended a review of an application by Organon & Co.’s atopic dermatitis (eczema) drug by three months with a new target date set for March next year.
Drugs Health Pharma

USFDA postpones Organon’s eczema drug review by three months

The US regulator has extended a review of an application by Organon & Co.’s atopic dermatitis (eczema) drug by three months with a.

Read More
Shanghai Henlius Biotech, Inc., and US-based Organon & Co. announced their end-stage trial for investigational breast cancer had met its main goal of an absence of cancer in treated patients.
Drugs Health Pharma

Henlius, Organon trial drug meets goal of an absence of breast cancer

Shanghai Henlius Biotech, Inc., and US-based Organon & Co. announced their end-stage trial for investigational breast cancer had met its main goal of.

Read More
US-based pharmaceutical company Organon & Co., will acquire Riovant Sciences Ltd’s arm — Dermavant Sciences Ltd., specialising in immuno-dermatology — for $1.2 billion.
Drugs Health Pharma

Organon & Co to buy Riovant’s arm Dermavant Sciences for $1.2 billion

US-based pharmaceutical company Organon & Co., will acquire Riovant Sciences Ltd’s arm — Dermavant Sciences Ltd., specialising in immuno-dermatology — for $1.2 billion.

Read More